• Explore /
  • Poster
  • / Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with <I>EGFR</I>-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

Abstract Poster

Authors

Yi-Long Wu

Yi-Long Wu

Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, Guangzhou, China

Yi-Long Wu , James Chih-Hsin Yang , Dong-Wan Kim , Wu-Chou Su , Myung-Ju Ahn , Dae Ho Lee , Johan F. Vansteenkiste , Li Zhang , Enriqueta Felip , Bin Peng , Ying Gong , Sylvia Zhao , Taro Amagasaki , Mikhail Akimov , Daniel Shao-Weng Tan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT01610336

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8017)

DOI

10.1200/jco.2014.32.15_suppl.8017

Abstract #

8017

Poster Bd #

31

Abstract Disclosures

Similar Posters

First Author: Yi-Long Wu

First Author: Qing Zhou

Poster

2016 ASCO Annual Meeting

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

First Author: Keunchil Park

First Author: Mariana da Rocha Almeida Brandao